Entrada Therapeutics (TRDA) Proxy filing summary

Executive summary

• The 2026 Annual Meeting will be held virtually on June 10, 2026, with shareholders able to vote electronically and submit questions online.

• Shareholders will vote on electing two Class II directors, ratifying the appointment of Ernst & Young LLP as auditor, and approving amendments to the 2021 Stock Option and Incentive Plan and the 2021 Employee Stock Purchase Plan.

• The board recommends voting in favor of all proposals and highlights the use of electronic proxy materials to reduce costs and environmental impact.

Voting matters and shareholder proposals

• Proposals include electing two Class II directors for three-year terms, ratifying Ernst & Young LLP as auditor for 2026, and approving amendments to the 2021 Stock Option and Incentive Plan and Employee Stock Purchase Plan to include pre-funded warrants in the evergreen calculation.

• Shareholders may submit proposals for the 2027 meeting by December 25, 2026, and must follow advance notice procedures for nominations or other business.

Board of directors and corporate governance

• The board is divided into three classes with staggered terms; nominees for Class II are Peter S. Kim, Ph.D., and Bernhardt Zeiher, M.D.

• Most directors are independent, with separate roles for chairman and CEO.

• Committees include audit, compensation, and nominating/governance, each with defined charters and responsibilities.

• The board emphasizes director independence, diversity of skills, and regular evaluation of governance practices.